- ¥180bn
- ¥206bn
- ¥247bn
Brief: R&I affirms Miraca Holdings's rating at "A" and says stable outlook
Table: Miraca Holdings -2017/18 group results
Table: Miraca Holdings -2017/18 parent results
Table: Miraca Holdings -2017/18 group forecast
Brief: Fujirebio Says Entered Into Agreement With Janssen Pharmaceuticals
Table: Miraca Holdings - 9-MTH group results
Brief: Morpho raises 499.7 mln yen through new share issue
Table: Miraca Holdings -2017/18 group forecast
Brief: Morpho says capital alliance with Miraca Holdings
Brief: Miraca Holdings to offer early-retirement program
Table: Miraca Holdings - 6-MTH group results
Brief: Avista Capital Partners to acquire Miraca Life Sciences
Brief: Miraca Holdings says change of unit
Table: Miraca Holdings Inc -2017 6-month group forecast
Table: Miraca Holdings -2017/18 group forecast
Brief: Morphotek announces agreement with Fujirebio Diagnostics to commercialize CA125 II assay as companion diagnostic for Farletuzumab
Table: Miraca Holdings -Q1 group results
Brief: Miraca Holdings says business transfer between two units
Table: Miraca Holdings -2016/17 parent results